09:43 AM EST, 01/02/2025 (MT Newswires) -- NRX Pharmaceuticals ( NRXP ) unit Hope Therapeutics said Thursday that it plans to acquire the Kadima Neuropsychiatry Institute.

Hope said Kadima would be the flagship clinic for its planned international network of interventional psychiatry clinics. It also said Kadima founder David Feifel would become Hope's chief medical innovation officer.

Financial terms of the deal were not disclosed.

Shares of NRX Pharmaceuticals ( NRXP ) were up 11% in recent trading.

Price: 2.45, Change: +0.25, Percent Change: +11.36